csirt@kutim:~/threat-intel/cve/CVE-2023-43632

Katalog CVE

CVSS 9.9 · Critical EPSS 0,66%

Kerentanan Memory Allocation with Excessive Size Value pada linuxfoundation edge virtualization engine. Skor CVSS 3.1 9.9 (Critical) menurut NVD.

Deskripsi (NVD)

As noted in the “VTPM.md” file in the eve documentation, “VTPM is a server listening on port 8877 in EVE, exposing limited functionality of the TPM to the clients. VTPM allows clients to execute tpm2-tools binaries from a list of hardcoded options” The communication with this server is done using protobuf, and the data is comprised of 2 parts: 1. Header 2. Data When a connection is made, the server is waiting for 4 bytes of data, which will be the header, and these 4 bytes would be parsed as uint32 size of the actual data to come. Then, in the function “handleRequest” this size is then used in order to allocate a payload on the stack for the incoming data. As this payload is allocated on the stack, this will allow overflowing the stack size allocated for the relevant process with freely controlled data. * An attacker can crash the system. * An attacker can gain control over the system, specifically on the “vtpm_server” process which has very high privileges.

Rincian

Terbit di NVD
21 September 2023
Terakhir diubah
17 Juni 2026
Status NVD
Modified
CVSS 3.1
9.9 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-789: Memory Allocation with Excessive Size Value
CWE-770: Allocation of Resources Without Limits or Throttling
EPSS (30 hari)
0,66% peluang dieksploitasi; lebih tinggi dari 50,1% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
linuxfoundation edge virtualization engine Versi 3.0.0 hingga sebelum 9.5.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.